Moreover, the results from this work have significant translational implications when considering that two RET kinase inhibitors, Pralsetinib and Selpercatinib, have recently been FDA-approved for non-small cell lung cancer (NSCLC) and RET+ advanced medullary thyroid cancer. Here, RET is linked to non-small cell lung carcinoma.